Dishman Carbogen Amcis (DCAL) Stock Overview
Provides contract research and manufacturing services for the pharmaceutical and healthcare industries worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
DCAL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Dishman Carbogen Amcis Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹284.05 |
| 52 Week High | ₹321.95 |
| 52 Week Low | ₹161.21 |
| Beta | 0.17 |
| 1 Month Change | 6.17% |
| 3 Month Change | 8.25% |
| 1 Year Change | 62.68% |
| 3 Year Change | 168.99% |
| 5 Year Change | 66.89% |
| Change since IPO | -19.32% |
Recent News & Updates
Recent updates
Is Dishman Carbogen Amcis (NSE:DCAL) Using Too Much Debt?
Jun 23
Dishman Carbogen Amcis Limited's (NSE:DCAL) Share Price Boosted 32% But Its Business Prospects Need A Lift Too
May 27These 4 Measures Indicate That Dishman Carbogen Amcis (NSE:DCAL) Is Using Debt In A Risky Way
Jan 16Dishman Carbogen Amcis Limited (NSE:DCAL) Shares Fly 28% But Investors Aren't Buying For Growth
Dec 04The Market Doesn't Like What It Sees From Dishman Carbogen Amcis Limited's (NSE:DCAL) Revenues Yet
Oct 15Why Investors Shouldn't Be Surprised By Dishman Carbogen Amcis Limited's (NSE:DCAL) 31% Share Price Plunge
Jun 01Dishman Carbogen Amcis Limited's (NSE:DCAL) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Feb 25Dishman Carbogen Amcis (NSE:DCAL) Takes On Some Risk With Its Use Of Debt
Dec 29Is Dishman Carbogen Amcis (NSE:DCAL) Using Too Much Debt?
Jun 22Is Dishman Carbogen Amcis (NSE:DCAL) A Risky Investment?
Feb 14Dishman Carbogen Amcis (NSE:DCAL) Use Of Debt Could Be Considered Risky
Jun 22Shareholders Will Be Pleased With The Quality of Dishman Carbogen Amcis' (NSE:DCAL) Earnings
May 18Dishman Carbogen Amcis (NSE:DCAL) Has A Pretty Healthy Balance Sheet
Mar 14We Think Dishman Carbogen Amcis (NSE:DCAL) Is Taking Some Risk With Its Debt
Aug 23Why Dishman Carbogen Amcis Limited (NSE:DCAL) Could Be Worth Watching
Apr 29Dishman Carbogen Amcis (NSE:DCAL) Has A Somewhat Strained Balance Sheet
Mar 16A Look At Dishman Carbogen Amcis' (NSE:DCAL) Share Price Returns
Feb 23How Much Are Dishman Carbogen Amcis Limited (NSE:DCAL) Insiders Spending On Buying Shares?
Feb 05Is Dishman Carbogen Amcis Limited (NSE:DCAL) Popular Amongst Institutions?
Jan 23
What We Learned About Dishman Carbogen Amcis' (NSE:DCAL) CEO Compensation
Jan 10Is Now An Opportune Moment To Examine Dishman Carbogen Amcis Limited (NSE:DCAL)?
Dec 23Dishman Carbogen Amcis (NSE:DCAL) Takes On Some Risk With Its Use Of Debt
Dec 05Dishman Carbogen Amcis Limited (NSE:DCAL) Shares Could Be 27% Below Their Intrinsic Value Estimate
Nov 17If You Had Bought Dishman Carbogen Amcis' (NSE:DCAL) Shares Three Years Ago You Would Be Down 47%
Oct 23What We Learned About Dishman Carbogen Amcis' (NSE:DCAL) CEO Compensation
Sep 27Is Now The Time To Look At Buying Dishman Carbogen Amcis Limited (NSE:DCAL)?
Sep 06Dishman Carbogen Amcis Limited's (NSE:DCAL) Share Price Could Signal Some Risk
Aug 03Dishman Carbogen Amcis Limited's (NSE:DCAL) Price In Tune With Earnings
Jul 20Market Cool On Dishman Carbogen Amcis Limited's (NSE:DCAL) Earnings
Jul 06Shareholder Returns
| DCAL | IN Life Sciences | IN Market | |
|---|---|---|---|
| 7D | 1.0% | 1.8% | 1.5% |
| 1Y | 62.7% | -0.4% | -4.7% |
Return vs Industry: DCAL exceeded the Indian Life Sciences industry which returned -3.2% over the past year.
Return vs Market: DCAL exceeded the Indian Market which returned -6% over the past year.
Price Volatility
| DCAL volatility | |
|---|---|
| DCAL Average Weekly Movement | 5.8% |
| Life Sciences Industry Average Movement | 5.2% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IN Market | 8.3% |
| 10% least volatile stocks in IN Market | 3.2% |
Stable Share Price: DCAL has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: DCAL's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 1,106 | Arpit Vyas | imdcal.com |
Dishman Carbogen Amcis Limited provides contract research and manufacturing services for the pharmaceutical and healthcare industries worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It offers cholesterol and vitamin D analogs; generic active pharmaceutical ingredients for diagnostics, ophthalmic treatments, laxatives, organophosphate antidotes; ammonium, phosphonium; quats, phosphoranes, and wittig reagents; cholesterol and lanolin-related products; sterile injectables; and softgel formulations, as well as hand and body wash, sanitisers, and antiseptics.
Dishman Carbogen Amcis Limited Fundamentals Summary
| DCAL fundamental statistics | |
|---|---|
| Market cap | ₹44.53b |
| Earnings (TTM) | ₹1.04b |
| Revenue (TTM) | ₹28.96b |
Is DCAL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DCAL income statement (TTM) | |
|---|---|
| Revenue | ₹28.96b |
| Cost of Revenue | ₹5.36b |
| Gross Profit | ₹23.59b |
| Other Expenses | ₹22.55b |
| Earnings | ₹1.04b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.65 |
| Gross Margin | 81.48% |
| Net Profit Margin | 3.60% |
| Debt/Equity Ratio | 41.0% |
How did DCAL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 09:50 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Dishman Carbogen Amcis Limited is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shikha Jain | Anand Rathi Shares and Stock Brokers Limited |
| Nikhil Shetty | BP Wealth Management Private Limited |
| Nitin Agarwal | DAM Capital Advisors |